Edition:
United Kingdom

GlycoMimetics Inc (GLYC.OQ)

GLYC.OQ on NASDAQ Stock Exchange Global Market

18.79USD
8:59pm GMT
Change (% chg)

$-1.46 (-7.21%)
Prev Close
$20.25
Open
$20.35
Day's High
$20.71
Day's Low
$18.47
Volume
192,048
Avg. Vol
158,375
52-wk High
$21.40
52-wk Low
$3.83

Chart for

About

GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment... (more)

Overall

Beta: 3.18
Market Cap(Mil.): $426.05
Shares Outstanding(Mil.): 32.72
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 84.57 16.44
EPS (TTM): -- -- --
ROI: -- 3.42 10.61
ROE: -- 5.38 14.21

BRIEF-GlycoMimetics qtrly loss per share $‍0.24

* Glycomimetics reports program updates and third quarter 2017 results

08 Nov 2017

BRIEF-GlycoMimetics says files for mixed shelf of upto $250 mln

* GlycoMimetics Inc says files for mixed shelf of upto $250.0 million - SEC filing‍​ Source text: (http://bit.ly/2xOoKE6) Further company coverage:

28 Sep 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $146.86 +1.10
Novartis AG (NOVN.S) CHF83.56 +0.02
Pfizer Inc. (PFE.N) $36.60 +0.06
Merck & Co., Inc. (MRK.N) $62.07 +3.41
Roche Holding Ltd. (ROG.S) CHF236.00 -8.40
Roche Holding Ltd. (RO.S) CHF239.40 -8.20
Bayer AG (BAYGn.DE) €104.52 +0.02
Bayer AG (BAYE.F) -- --

Earnings vs. Estimates